Core Insights - Daxor Corporation has expanded its blood volume analysis (BVA) technology at two major hospitals within New Jersey's largest academic health care system, anticipating continued sales growth throughout 2025 [1][2][3] - The implementation of on-site BVA analyzers at these hospitals will provide immediate access to precise blood volume measurements, enhancing fluid management and improving patient outcomes, particularly for heart failure and critical care patients [2][3] - The CEO of Daxor highlighted that the expansion reflects the effectiveness of the company's growth strategy and the increasing recognition of the importance of blood volume analysis technology in patient care [3] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, with its BVA-100 being the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted at leading hospital centers across the U.S., contributing to improved hospital performance metrics and significantly reducing mortality and readmissions in heart failure and critical care [3] - The company is engaged in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3]
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals